argenx SE American Depositary Shares ARGX

argenx SE, anteriormente arGEN X BV, es una empresa biofarmacéutica con sede en los Países Bajos. Crea y desarrolla una cartera de terapéuticas de anticuerpos diferenciados utilizando su plataforma de descubrimiento, Simple Antibody, la cual explota las características del sistema inmunitario de la llama. La empresa desarrolla una cartera de terapéuticas de anticuerpos centradas en el cáncer y las enfermedades autoinmunes. Incluye: ARGX-110, un anticuerpo para malignidades hematológicas y tumores sólidos, que modula funciones del tumor como la proliferación celular y la supervivencia; ARGX-111, un antagonista de c-Met, un receptor tirosina quinasa involucrado en la proliferación celular, angiogénesis y metástasis en múltiples tumores sólidos; ARGX-112, un antígeno que apunta a la dermatitis atópica mediante la neutralización de la señalización mediada por IL-20 e IL-22 (interleucina) a través del bloqueo de su receptor común, entre otros.

• The Motley Fool 5 oct

  10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?

  Wall Street analysts are overwhelmingly bullish on Argenx SE (ARGX), with 10 analysts predicting the stock will reach at least $1,200 within 12 months from its current price of $919, representing potential upside of roughly 29%. The optimism is driven by strong sales growth from its Vyvgart franchise and a promising pipeline of autoimmune disease treatments. However, the company faces risks from ongoing clinical trials and declining sales in China.

  

• GlobeNewswire Inc. 29 sept

  argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

  argenx presented new clinical data at the AANEM and MGFA scientific sessions demonstrating deepening improvements in ocular myasthenia gravis (MG) with VYVGART, sustained one-year efficacy in anti-AChR antibody-negative MG patients, and benefits of earlier treatment initiation. Real-world evidence from over 1,100 U.S. MG patients showed greater clinical gains when treatment started within one year of diagnosis. Long-term CIDP data reinforced consistent safety and efficacy, with a Phase 4 study supporting direct transition from IVIg. Pipeline candidates empasiprubart and adimanebart showed promising Phase 2 results in multifocal motor neuropathy and congenital myasthenic syndrome respectively.

  

• GlobeNewswire Inc. 27 ago

  argenx Completes Acquisition of Forte Biosciences, Inc.

  argenx successfully completed its acquisition of Forte Biosciences for $77.00 per share in cash, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease. The acquisition expands argenx's immunology portfolio and supports its Vision 2030 strategy to become a leading immunology innovation company by targeting diseases with limited treatment options.

  

• GlobeNewswire Inc. 6 ago

  argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

  argenx announced a tender offer to acquire Forte Biosciences for $77 per share in cash. The acquisition adds Forte's first-in-class anti-CD122 monoclonal antibody FB102 to argenx's immunology pipeline. The tender offer commenced on August 6, 2026, with an expiration date of August 26, 2026, and is not subject to a financing condition. Forte's Board of Directors has recommended stockholders accept the offer.

  

• GlobeNewswire Inc. 23 jun

  argenx to Host Autoimmune Myositis R&D Webinar

  argenx will host a webinar on June 23, 2026, to discuss advancing FcRn leadership into autoimmune myositis. The company will present data on efgartigimod showing sustained patient benefits in myositis and Sjogren's disease, with management and external key opinion leaders from leading medical institutions participating.